We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
By Olivia Bugault
Novartis AG said Saturday that pooled data from three phase III trials show that Inclisiran, an investigational treatment for hyperlipidemia in adults, has positive safety and efficacy results.
Data from the three trials, Orion-9, Orion-10 and Orion-11, "showed a durable and potent reduction in LDL-cholesterol of 51% when used in addition to other lipid-lowering therapies over 17 months of treatment," the pharmaceutical giant said.
The analysis is consistent with findings recently released in the New England Journal of Medicine, it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
March 30, 2020 01:43 ET (05:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
